International Niemann–Pick Disease Alliance

Menu

Uncategorised

Explore

Categories

  1. Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

    • 25.03.21
    Read story

  2. Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

    • 10.03.21
    Read story

  3. Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

    • 09.03.21
    Read story

  4. Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    • 04.03.21
    Read story

  5. Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families

    • 22.02.21
    Read story

  6. Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

    • 26.01.21
    Read story

  7. Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering

    • 10.12.20
    Read story

  8. Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    • 08.09.20
    Read story

  9. Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

    • 19.05.20
    Read story

  10. A message from Orphazyme to the global community of patients, family members and healthcare providers impacted by the corona virus pandemic (COVID-19):

    • 27.03.20
    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...